Tag: NASDAQ: ADMP

Business

Adamis Pharmaceuticals Corp (NASDAQ: ADMP) Offers to Apprise on ZIMHI™

Adamis Pharmaceuticals Corp (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged for appraisal the company’s resubmitted New Drug Application (NDA) for ZIMHI™. FDA finishes filing appraisal and governs NDA adequately ample for fundamental appraisal Adamis has received FDA communication involving the company’s NDA, affirming […]

Business

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) Starts Study on COVID-19 Treatment, Stock Dips

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) dropped 1.96% after the company announced that start-up activities for the clinical trial of its experimental COVID-19 treatment, Tempol, are underway. The company is conducting the activities in collaboration with an extensive clinical research organization.  Adamis commence activities on a COVID-19 treatment study Already, site […]

Business

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) Up 6.93% After FDA Accepts to Review its ZIMHI NDA

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) gained 6.93% following the announcement that the FDA had accepted to review its resubmitted New Drug Application for ZIMHI™. ZIMHI is a higher naloxone injection product candidate under development by the company for opioid overdose treatment. It lost 5.56% in the last trading session. The […]

Business

Will The Development Of Tempo Work For Adamis Pharmaceuticals Corp (NASDAQ: ADMP) Lead to A Sudden Climb In Stock

Adamis Pharmaceuticals Corp (NASDAQ: ADMP) is excited about its rise in stock that stood at 55.7%. Before that, the company stock had declined by 11.50% to settle at $1.00. This “climb,” coupled with its Covid-19 therapy endeavors that seem to be nearing the finish line, continues to inspire hope among […]